PT - JOURNAL ARTICLE AU - Sandeep Budhiraja AU - Mona Aggarwal AU - Rebecca Wig AU - Akansha Tyagi AU - RS Mishra AU - Monica Mahajan AU - Jay Kirtani AU - Rommel Tickoo AU - Supriya Bali AU - Arun Dewan AU - Ritesh Aggarwal AU - Prashant Saxena AU - Namrita Singh AU - Ashok Kumar AU - I. M. Chugh AU - Pankaj Aneja AU - Sanjay Dhall AU - Vandana Boobna AU - Vineet Arora AU - Sujeet Jha AU - Abhaya Indrayan TI - Long Term Health Consequences of COVID-19 in Hospitalized Patients from North India: A follow up study of upto 12 months AID - 10.1101/2021.06.21.21258543 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.21.21258543 4099 - http://medrxiv.org/content/early/2021/10/14/2021.06.21.21258543.short 4100 - http://medrxiv.org/content/early/2021/10/14/2021.06.21.21258543.full AB - Background Long-COVID syndrome is now a real and pressing public health concern. We cannot reliably predict who will recover quickly or suffer with mild debilitating long COVID-19 symptoms or battle life-threatening complications. In order to address some of these questions, we studied the presence of symptoms and various correlates in COVID-19 patients who were discharged from hospital, 3 months and up to 12 months after acute COVID-19 illness.Methods This is an observational follow-up study of RT-PCR confirmed COVID-19 patients admitted at 3 hospitals in north India between April – August 2020. Patients were interviewed telephonically using a questionnaire regarding the post-COVID symptoms. The first tele-calling was done in the month of September 2020, which corresponded to 4-16 weeks after disease onset. All those who reported presence of long COVID symptoms, were followed-up with a second call, in the month of March 2021, corresponding to around 9-12 months after the onset of disease.Results Of 990 patients who responded to the first call, 615 (62.2%) had mild illness, 227 (22.9%) had moderate and 148 (15.0%) had severe COVID-19 illness at the time of admission. Nearly 40% (399) of these 990 patients reported at least one symptom at that time. Of these 399 long-COVID patients, 311 (almost 78%) responded to the second follow-up. Nearly 8% reported ongoing symptomatic COVID, lasting 1-3 months and 32% patients having post-COVID phase with symptoms lasting 3-12 months. Nearly 11% patients continued to have at least one symptom even at the time of the second interview (9-12 months after the disease onset). Overall, we observed Long-COVID in almost 40% of our study group. Incidence of the symptoms in both the follow-ups remained almost same across age-groups, gender, severity of illness at admission and presence of comorbidity, with no significant association with any of them. Most common symptoms experienced in long COVID phase in our cohort were fatigue, myalgia, neuro-psychiatric symptoms like depression, anxiety, “brain fog” and sleep disorder, and breathlessness. Fatigue was found to be significantly more often reported in the elderly population and in those patients who had a severe COVID-19 illness at the time of admission. Persistence of breathlessness was also reported significantly more often in those who had severe disease at the onset. The overall median duration of long COVID symptoms was 16.9 weeks with inter-quartile range of 12.4 to 35.6 weeks. The duration of symptom resolution was not associated with age, gender or comorbidity but was significantly associated with severity of illness at the time of admission (P=0.006).Conclusions Long-COVID is now being recognized as a new disease entity, which includes a constellation of symptoms. Long-COVID was in almost 40% of our study group with no correlation to age, gender, comorbidities or to the disease severity. The duration of symptom resolution was significantly associated with severity of illness at the time of admission (P = 0.006). In our study, all patients reported minor symptoms such as fatigue, myalgia, neuro-psychiatric symptoms like depression, anxiety, “brain fog” and sleep disorder and persistence of breathlessness. Severe organ damage was not reported by our subjects. This might be the longest post-COVID follow-up study on a sample of nearly 1000 cases from India.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any financial contribution from any funding agency/source.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study titled Long term health consequences of COVID19 in hospitalized patients from North India: A follow up study of upto 12 months was approved by the Institutional Ethics Committee, Max Super Specialty Hospital (A unit of Devki Devi Foundation); address: service floor, office of Ethics Committee, East Block, Next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21 14, dated 18th June2021. This approval has been given as a no objection for publication of the manuscript. The IEC has observed that study was given approval earlier by the same Ethics committee in the beginning on 20th April2020 vide ref. no. RS/MSSH/DDF/SKT-2/IEC/IM/20-16.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data available in manuscript